<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Guanylyl cyclase C (GUCY2C) is the index <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mucosa antigen, an emerging class of immunotherapeutic targets for the prevention of recurrent <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> originating in visceral epithelia </plain></SENT>
<SENT sid="1" pm="."><plain>GUCY2C is an autoantigen principally expressed by intestinal epithelium, and universally by primary and metastatic <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Immunization with adenovirus expressing the structurally unique GUCY2C extracellular domain (GUCY2C(<z:mp ids='MP_0010412'>ECD</z:mp>); Ad5-GUCY2C) produces prophylactic and therapeutic protection against GUCY2C-expressing <z:hpo ids='HP_0003003'>colon cancer</z:hpo> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in mice, without collateral <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>GUCY2C antitumor efficacy is mediated by a unique immunological mechanism involving lineage-specific induction of antigen-targeted CD8(+) T cells, without CD4(+) T cells or B cells </plain></SENT>
<SENT sid="4" pm="."><plain>Here, the unusual lineage specificity of this response was explored by integrating high-throughput <z:chebi fb="7" ids="16670">peptide</z:chebi> screening and bioinformatics, revealing the role for GUCY2C-directed CD8(+) T cells targeting specific <z:chebi fb="0" ids="53000">epitopes</z:chebi> in antitumor efficacy </plain></SENT>
<SENT sid="5" pm="."><plain>In BALB/c mice vaccinated with Ad5-GUCY2C, CD8(+) T cells recognize the dominant GUCY2C(254-262) <z:chebi fb="0" ids="53000">epitope</z:chebi> in the context of H-2K(d), driving critical effector functions including interferon gamma secretion, cytolysis ex vivo and in vivo, and antitumor efficacy </plain></SENT>
<SENT sid="6" pm="."><plain>The ability of GUCY2C to induce lineage-specific responses targeted to cytotoxic CD8(+) T cells recognizing a single <z:chebi fb="0" ids="53000">epitope</z:chebi> mediating antitumor efficacy without <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> highlights the immediate translational potential of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mucosa antigen-based vaccines for preventing <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> of mucosa-derived <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>